The stock is in a pronounced downtrend, with a 1-year price change of -16.76% and a 6-month decline of -31.83%, significantly underperforming the SPY's 27.04% and 10.41% gains over the same periods. Currently trading at $52.26, the price sits approximately 17% above its 52-week low of $41.73 but 50% below its 52-week high of $104.32, indicating it is in the lower quartile of its annual range and suggesting a potential value opportunity, though the persistent downtrend warns of continued weakness. Recent momentum shows a slight divergence, with a 1-month decline of -3.35% compared to a flat 3-month performance (0.0%), yet both periods show severe negative relative strength versus the market (-7.95 and -12.6, respectively), indicating the stock's weakness is persistent and broad-based, not just a short-term pullback. Key technical levels are clearly defined, with immediate support at the 52-week low of $41.73 and resistance at the recent high near $77 from December 2025; a breakdown below $41.73 would signal a new leg down, while a sustained move above $60 is needed to suggest a meaningful reversal, with the stock's high short ratio of 5.44 indicating significant bearish sentiment that could fuel a sharp rally on any positive catalyst.

Revenue growth is exceptionally strong but shows signs of sequential deceleration; Q4 2025 revenue reached $367.2 million, representing a robust 82.98% year-over-year increase, yet this follows even higher growth rates in prior quarters, with Q3 revenue at $334.2 million. The company's gross margin improved dramatically to 89.74% in Q4 from 61.61% in Q3, driven by a favorable revenue mix, but this stellar profitability at the gross level has not translated to the bottom line. The company remains deeply unprofitable, with a Q4 net loss of $54.2 million, contributing to a trailing twelve-month free cash flow of -$404.0 million, and the net margin was -14.75%, though this is an improvement from the -23.93% net margin in Q3, indicating losses are narrowing on a relative basis as revenue scales. The balance sheet shows a strong current ratio of 3.13, providing ample liquidity, but financial health is pressured by a debt-to-equity ratio of 1.66 and deeply negative returns on assets and equity (-9.07% and -49.87%, respectively), signaling the company is heavily reliant on external financing to fund its operations and growth given its substantial cash burn.